{"id":"W2334974730","doi":"10.1097/coc.0b013e31820dbdcc","title":"A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma","year":2011,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Progressive disease; Regimen; Nasopharyngeal carcinoma; Erlotinib Hydrochloride; Cisplatin; Gastroenterology; Cancer; Radiation therapy; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006691323,0.0002052549,0.002337492,0.000139992,0.00002388305,0.000001640798,0.0000784271,0.00005349458,0.0001315201],"category_scores_gemma":[0.0004369101,0.0001128246,0.0002156861,0.0002023832,0.0006798212,0.00004798819,0.00002101344,0.0003105805,0.000001042062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001941398,"about_ca_system_score_gemma":0.001451865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001209851,"about_ca_topic_score_gemma":0.00009965638,"domain_scores_codex":[0.9973232,0.000306038,0.001609118,0.0002309803,0.0002626746,0.0002679639],"domain_scores_gemma":[0.9972168,0.0007368135,0.001351172,0.0001604668,0.0002550619,0.0002797403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5956151,0.01266058,0.06087846,0.00001724015,0.0003031773,0.0003546532,0.001238918,3.510005e-7,0.000002295965,0.000002868258,0.00004823309,0.3288781],"study_design_scores_gemma":[0.3420303,0.4821647,0.1739431,0.000155372,0.000273335,0.00002761653,0.0002171506,0.00002629766,0.00002616602,0.000008954278,0.001043429,0.00008355544],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973937,0.0001754132,0.00002703502,0.001192302,0.0002703156,0.0006686654,0.00001342509,0.000004088021,0.0002550853],"genre_scores_gemma":[0.9932544,0.0002874232,0.005051739,0.001151552,0.0001527377,0.00004076573,0.000002317882,0.00001911521,0.00003991333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4695041,"threshold_uncertainty_score":0.4600855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08404970786032828,"score_gpt":0.4195930154508751,"score_spread":0.3355433075905468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}